Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bms-387032. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 19/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 13/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 8/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 8/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 3/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 1.00 |
| ▸ | PAK3 | O75914 | 1/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-387032 SCHEMBL20583046 | 0.99 | CDK2 (0.98) | CDK2CDK9CCNE2CCNE1CDK7 | |
| SCHEMBL24528966 | 0.91 | CDK2 (0.83) | CDK2CDK9CCNE2CCNE1CDK7 | |
| SCHEMBL14067131 | 0.90 | CDK2 (0.82) | CDK2CDK9CCNE2CCNE1CDK7 | |
| SCHEMBL17148365 | 0.90 | CDK2 (0.81) | CDK2CDK9CCNE2CCNE1CDK7 | |
| SCHEMBL4731289 | 0.90 | CDK2 (1.00) | CDK2CDK9CCNE2CCNE1CDK7 | |
| SCHEMBL4730239 | 0.90 | CDK2 (1.00) | CDK2CDK9CCNE2CCNE1CDK7 | |
| SCHEMBL4733685 | 0.90 | CDK2 (1.00) | CDK2CDK9CCNE2CCNE1CDK7 | |
| SCHEMBL14093617 | 0.89 | CDK2 (0.84) | CDK2CDK9CCNE2CCNE1CDK7 | |
| Hydrochloric Acid SCHEMBL6183632 | 0.89 | CDK2 (0.98) | CDK2CDK9CCNE2CCNE1CDK7 | |
| Hydrochloric Acid SCHEMBL6183918 | 0.89 | CDK2 (0.98) | CDK2CDK9CCNE2CCNE1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2248 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076952-A1 | Agent for Treatment of Neutropenia | UNIV TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2026-03-19 | — | — | US | claimed |
| US-20260053750-A1 | INHALABLE COMPOSITIONS OF CDK9 INHIBITORS | OWEN MATTHEW (US) | 2026-02-26 | — | — | US | claimed |
| EP-4683632-A1 | A CYCLIN-DEPENDENT KINASE 2/4/9 INHIBITOR FOR THE TREATMENT OF NEUTROPENIA | Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| WO-2025202647-A1 | CDK INHIBITORS CONJUGATED TO EGFR TARGETING MOIETIES | KING'S COLLEGE LONDON (GB) | 2025-10-02 | — | — | WO | claimed |
| EP-4572804-A2 | INHALABLE COMPOSITIONS OF CDK9 INHIBITORS | The Regents of the University of California (US) | 2025-06-25 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119798262-A | CDK9/EZH2 double-target inhibitor, and medicinal composition and application thereof | 烟台新药创制山东省实验室 | 2025-04-11 | — | — | CN | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| US-20250034202-A1 | CELASTROL PROTEOLYSIS TARGETING CHIMERAS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-01-30 | — | — | US | claimed |
| US-6515004-B1 | Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | claimed |
| EP-1272193-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Bristol-Myers Squibb Company (US) | 2003-01-08 | — | — | EP | claimed |
| EP-1240166-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-18 | — | — | EP | claimed |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-23 | — | — | US | claimed |
| WO-2002010162-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL] CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | claimed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | claimed |
| WO-2001044242-A9 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001080813-A2 | METHODS FOR PREVENTING AND TREATING ALOPECIA INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2001072721-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-04 | — | — | WO | claimed |
| WO-2001044242-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | claimed |